In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be saturated. We studied the effect of trastuzumab t...
Saved in:
Main Authors: | Sietske B.M. Gaykema, Johan R. de Jong, Patrick J. Perik, Adrienne H. Brouwers, Carolien P. Schröder, Thijs H. Oude Munnink, Alphons H.H. Bongaerts, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-07-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.2310/7290.2014.00011 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
by: Sylvana Hidalgo, et al.
Published: (2013-01-01) -
Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab
by: Lauren Klute, et al.
Published: (2020-01-01) -
Trastuzumab Resistance: Role for Notch Signaling
by: Kinnari Mehta, et al.
Published: (2009-01-01) -
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)